Christian Hackenberger
Christian P. R. Hackenberger studied chemistry in Freiburg and Madison/Wisconsin (M.Sc. with Prof. Sam Gellman) and performed his doctoral studies in organic chemistry at the RTWH Aachen with Prof. Carsten Bolm. After a postdoctoral stay at MIT with Prof. Barbara Imperiali, he founded his own research group at the Freie Universität Berlin in 2005 as an Emmy Noether fellow. In 2012, he was appointed as Leibniz-Humboldt Professor and Department Head for Chemical Biology at the Leibniz-Research Institute for Molecular Pharmacology (FMP Berlin) and the Humboldt Universität zu Berlin. In addition, he is an associate editor for Chemical Science, the flagship journal of the Royal Society of Chemistry and authored over 140 publications.
His group develops highly selective chemical and chemoenzymatic strategies to functionalize proteins and antibodies to generate protein-based therapeutics against cancer, Alzheimer and viral infections. His laboratory invented P5-labeling, a superior bioconjugation platform to generate stable and efficacious antibody-drug-conjugates (ADCs). In addition, he pioneered the development of cell-permeable nanobodies and antibodies for intracellular targeting and the engineering of structurally defined protein-based antiviral compounds.
Christian is a co-founder of the Munich-based company Tubulis, which engineers better tolerable cancer drugs, especially ADCs, using conjugation technologies from his lab, in particular the P5-labeling platform. Recent awards include the Leonidas Zervas Award from the European Peptide Society (2018), the Astra Zeneca Award from the Royal Society of Chemistry (2023) and the Max-Bergmann Medal (2024). In 2020, he was the first recipient of the Falling Walls breakthrough of the year award in the Life Sciences, recognizing his contributions to develop next-generation biopharmaceuticals.
Abstracts this author is presenting: